16 closest matches · ranked by relevance
Chronic Lymphocytic Leukemia With 17p Deletion · Small Lymphocytic Lymphoma With 17p Deletion
Primary: Overall Response Rate — 77.8 % of participants with response by PI
Chronic Lymphocytic Leukemia · 17p Deletion · Cancer of the Blood and Bone Marrow
Primary: Overall Response Rate (Main Cohort) — 77.1 percentage of participants — p=<0.001
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Response Based on Overall Response Rate — 17; 11; 28; 6 Participants
Anaplastic Large Cell Lymphoma · Recurrent Adult Hodgkin Lymphoma · Recurrent Mantle Cell Lymphoma
Primary: Number of Patients With Response — 0; 2 participants
B-Cell Chronic Lymphocytic Leukemia · B-Lymphocytic Leukemia, Chronic · Chronic Lymphocytic Leukemia
Primary: Number of Participants With Complete Response of the Combination of Ibrutinib, Fludarabine, and Pembrolizumab in Patients With High-risk and/or Relapsed/Refractory…
High-grade Serous Ovarian Cancer
Primary: Overall Response Rate (ORR) — 1; 0; 0; 0 Participants
Non Small-cell Lung Cancer
Primary: FISH, IHC, RT-qPCR Comparison — 18; 15; 5; 182 participants — p=< 0.05
Hippel-Lindau Disease · Kidney Cancer
Primary: Number of Participants With a Renal Tumor Response — 0 participants
MDS
Primary: Complete Response Rate (CR) — 27; 17 Participants
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
Primary: Phase Ib: Dose-limiting Toxicities (DLT) (See Description) of Combined APR-246 and Carboplatin/PLD Regimen — 0; 1; 0 Participants
Anti-p53 TCR-Gene
Primary: Clinical Tumor Regression — 1 Participants
Lymphoma, Non-Hodgkin · Lymphoma, Nonhodgkin · Lymphoma, B-Cell
Primary: Overall Response Rate (ORR) — 80.3 Percent of Participants — p=<.0001
Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL)
Primary: Percentage of Participants Achieving Low Tumor Burden Status With Induction of Obinutuzumab or Obinutuzumab Plus Bendamustine (Debulking Period) — 81.4; 83.9; 88.3; 87.1…
Myeloid Malignancy
Primary: To Evaluate the Tolerabililty and the Incidence of Treatment-Emergent Adverse Events of Administration of APR 246 in Combination With Venetoclax and Azacitidine in…
Acute Myeloid Leukemia or Myelodysplastic Syndromes
Primary: To Assess Relapse-free Survival (RFS) in Patients With TP53 Mutated AML or MDS After Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT). — 12.5 months
Chronic Lymphocytic Leukemia
Primary: Complete Remission Rate in Participants Not Previously Treated With BCRi Therapy - Primary Analysis — 35.1 percentage of participants — p=<0.001